Ventricular septal defect (VSD) is the most common congenital cardiac malformation, mostly alone or in combination with other malformations. The incidence of this disease accounts for approximately 0.3% of live newborns and 25% to 30% of congenital cardiovascular diseases. Because VSD has a relatively high rate of natural closure, it accounts for approximately 10% of congenital cardiovascular disease in adults. Among the 1085 cases of congenital heart disease reported in the early literature in Shanghai, VSD accounted for 15.5%, with slightly more women than men. The traditional treatment is surgery, but surgical treatment is highly invasive, has a high complication rate, takes up many medical resources, and has some adverse psychological effects on patients after surgery. Since 1988, when Lock et al. first applied the double-sided umbrella to close VSD, several devices have been used in the interventional treatment of transcatheter VSD, such as the CardioSEAL double-sided umbrella, Sideris button patch and spring ring, but they have not been clinically applied due to the difficulty of operation, many complications and high incidence of residual shunts. In 2002, Amplatzer developed the perimembranous eccentric VSD blocker based on the development of atrial septal defect blocker and arteriovenous occlusion blocker and successfully applied it in the clinic, so that the global interventional treatment of ventricular septal defect has been developed rapidly and the number of treatment cases has increased exponentially, showing its obvious therapeutic advantages, however, certain guidelines should be mastered before interventional treatment: Qinghai Cardiovascular Disease (1) Clear indications 1. perimembranous VSD (1) Age: usually ≥ 5 years. (2) Weight > 15 Kg. (3) Simple VSD with hemodynamic abnormalities, diameter > 3 mm, < 14 mm. (4) VSD with the upper edge ≥ 2 mm from the right coronary valve of the aorta, without aortic right coronary valve detachment into the VSD and aortic regurgitation. (5) Ultrasound at the position of 9-12 points in the short-axis five-chamber heart section of the great vessels. (2) Myocardial VSD > 3 mm. (3) Residual shunt after surgical procedure. (2) Relative indications 1. small VSDs less than 3 mm in diameter without significant hemodynamic abnormalities. there are clinical cases of infective endocarditis complicated by the presence of small VSDs, therefore, the goal of blocking treatment is to avoid or reduce the number of patients with infective endocarditis complicated by small VSDs. In adult patients, the aortic valve prolapse is often combined with an intracristal VSD, and the size of the VSD is often underestimated by ultrasound and left ventriculography. Although this type of VSD is close to the aortic valve, according to current interventional experience, if the defect is more than 2 mm from the pulmonary valve and less than 5 mm in diameter, it can be successfully occluded in most patients, but its long-term outcome needs to be followed up. 3. 3 months after the cure of infective endocarditis, there is no redundancy in the heart cavity. 4. The upper edge of VSD is ≤ 2 mm from the right coronary valve of the aorta, and there is no prolapse of the right coronary sinus of the aorta, no combined aortic regurgitation, or combined with mild aortic regurgitation. 5. VSD combined with first-degree AV block or second-degree type I AV block. 6. VSD combined with PDA, PDA has indications for interventional treatment. 7. Porous VSD with bulging aneurysm, the upper edge of the defect is more than 2 mm from the aortic valve, the outlet is relatively concentrated, and the left ventricular surface of the blocker can completely cover the entire entrance. (C) Contraindications 1. Infectious endocarditis, intracardiac bulky organisms, or other infectious diseases. 2. Presence of thrombus at the placement of the blocker, or venous thrombosis in the catheter insertion pathway. 3. Huge VSD, poor anatomical position of the defect, and the blocker placement may affect the function of the aortic valve or atrioventricular valve. 4. Severe pulmonary hypertension with bidirectional shunt. 5. Combined bleeding disorders and thrombocytopenia. 6. Combination of significant liver and renal abnormalities. 7. Cardiac insufficiency, unable to tolerate the operation.